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Abstract
Background: Very few studies have explored the distinguishing features of severe asthma in childhood in Europe,
and only one study was conducted in Southern Europe. The aim of this study was to provide a detailed characterization
of children with severe asthma treated in specialized pediatric asthma centers across Italy.
Methods: We conducted a web-based data collection of family, environmental, clinical and laboratory characteristics of
41 patients aged 6–17 years with severe asthma, defined according to the recent guidelines of the European Respiratory
Society and the American Thoracic Society, and 78 age-matched peers with non-severe persistent asthma. The patients
have been enrolled from 16 hospital-based pediatric pulmonology and allergy centers in Northern, Central, and Southern
Italy. Logistic regression analysis assessed the relationship between patients’ characteristics and severe asthma
or non-severe persistent asthma.
Results: Features independently and significantly associated with severe asthma included lifetime sensitization
to food allergens [Odds ratio (OR), 4.73; 95 % Confidence Interval (CI), 1.21–18.53; p= 0.03], lifetime hospitalization for
asthma (OR, 3.71; 95 % CI, 1.11–12.33; p = 0.03), emergency-department visits for asthma during the past year (OR = 11.98;
95 % CI, 2.70–53.11; p = 0.001), and symptoms triggered by physical activity (OR = 12.78; 95 % CI, 2.66–61.40; p = 0.001).
Quality-of-life score was worse in patients with severe asthma than in subjects with non-severe persistent asthma
(5.9 versus 6.6, p = 0.005). Self-perception of wellbeing was compromised in more than 40 % of patients in both groups.
Children with severe asthma had lower spirometric z scores than non-severe asthmatic peers (all p < 0.001), although
56 % of them had a normal forced expiratory volume in 1 s. No differences were found between the two groups for
parental education, home environment, patients’ comorbidities, adherence to therapy, exhaled nitric oxide values, and
serum eosinophils and IgE .
Conclusions: As expected, children with severe asthma had more severe clinical course and worse lung function than
peers with non-severe persistent asthma. Unlike previous reports, we found greater sensitization to food allergens and
similar environmental and personal characteristics in patients with severe asthma compared to those with non-severe
persistent asthma. Psychological aspects are compromised in a large number of cases and deserve further investigation.
Keywords: Asthma, Atopy, Children, Lung function, Quality of life
* Correspondence: f.rusconi@meyer.it
14Epidemiology Unit, A. Meyer Children’s University Hospital, Viale Pieraccini
24, 50139 Florence, Italy
Full list of author information is available at the end of the article
© 2016 Montella et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Montella et al. Italian Journal of Pediatrics  (2016) 42:9 
DOI 10.1186/s13052-016-0217-z
Background
The vast majority of asthmatic children exhibit a mild or
moderate form of the disease, and only a small propor-
tion requires aggressive maintenance therapy for several
months or remains difficult-to-treat [1]. Nevertheless,
these children account for a relatively large amount of
resource expenditure among asthmatic patients [1, 2]. In
the last few years, guidelines and consensus documents
have been implemented to address the problem of
poorly controlled asthma and to provide a uniform def-
inition of severe asthma (SA) in children [3–5]. A Global
Allergy and Asthma European Network (GA2LEN) task
force suggested a reasoned approach to children with
problematic SA and proposed recommendations for its
assessment and treatment [5]. Recently, a joint Task
Force supported by the European Respiratory Society (ERS)
and the American Thoracic Society (ATS) reviewed the ter-
minology and provided evidence-based recommendations
for defining and treating SA in children and adults [2].
So far, very few studies have explored the distinguishing
features of SA in childhood [6–10], and due to the lack of a
recognized international definition of SA, inclusion criteria
and study design were heterogeneous. Two studies were
carried out in the United States [6, 7]. The first was a large
study on patients with either severe or difficult-to-treat
asthma enrolled in the TENOR (The Epidemiology and
Natural History of Asthma: Outcomes and Treatment Regi-
mens) study [6]. The other study recruited children across
five large academic centers participating in the Severe
Asthma Research Program supported by the National
Heart, Lung and Blood Institute [7]. Only three studies
were performed in Europe, specifically in France [8],
Sweden [9], and Norway [10], and enrolled smaller sample
sizes than those from the United States. Furthermore, while
studies from Northern Europe recruited children in several
hospitals and university clinics [9, 10], the French study en-
rolled patients from a single specialized center [8]. There-
fore, data on pediatric SA in Europe, and particularly in
Southern Europe, are still scarce. Identifying the distinctive
characteristics of children with SA may be useful not only
for improving scientific knowledge of SA-related risk fac-
tors and phenotypes, but also as the basis for developing
tailored approaches to asthma-patient management.
The aim of this study was to provide a detailed
characterization of children treated in specialized pediatric
asthma centers across Italy who complied with the recent
ERS/ATS definition of SA [2], and to compare these chil-




In the current multicenter, case–control study, children
and adolescents aged 6–17 years with SA and NSPA
were enrolled at outpatient hospital clinics by trained
pediatric pulmonologists and allergists between May
2013 and June 2014. The study was promoted and sup-
ported by the Italian Society of Pediatric Respiratory
Diseases (SIMRI). Inclusion criteria for all subjects were:
confirmed diagnosis of asthma, defined as ≥12 % change
in FEV1 after bronchodilator administration; evaluation
and management of the patient at the study center for
more than three months in order to exclude differential
diagnoses (Additional file 1) and address comorbidities
and contributory factors. Patients were defined as having
SA if they required treatment with high doses of inhaled
corticosteroids (Additional file 2) plus at least another
controller for at least 6 months in the previous year and
still ongoing at the time of recruitment. They also had
to meet at least one of the following criteria in the pre-
ceding year: at least two asthma exacerbations requiring
systemic corticosteroids for more than 3 days; daytime
and/or nighttime asthmatic symptoms and/or daily ac-
tivity limitation more than twice a week for at least
3 months; persistent airflow obstruction despite admin-
istration of oral steroids and bronchodilators for at least
2 weeks (Additional file 2).
For each SA case enrolled, the centers had to recruit 2
age-matched (+/−2 years at most) peers with NSPA (oc-
casional asthmatic symptoms and less than 2 exacerba-
tions requiring systemic steroids in the preceding year)
controlled by lower doses of inhaled corticosteroids than
those required for inclusion in the SA group (Additional
file 2) [1]. The study was approved by the ethics com-
mittee of the coordinating center (“Anna Meyer”
Pediatric University Hospital, Florence; approval num-
ber: 245, year 2012), and informed written consent was
obtained from the parent/legal guardian of each child
prior to the study inclusion. All children agreed to take
part in the study.
Clinical and laboratory assessment
Parents of all the enrolled subjects were interviewed by
means of a modified version of the SIDRIA question-
naire [11], including enquiries regarding the following
items: parents’ country of birth, education, history of
asthma and other allergic or respiratory diseases, smok-
ing habits, and working days lost in the past year be-
cause of their child’s asthma; indoor and outdoor
environment, including pets, dampness in the home,
number of cohabitants, and heavy traffic in the street of
residence; the patient’s physical activity, comorbidities,
and history of anaphylaxis, atopic eczema, allergic rhin-
itis, and food allergies (diagnosed on the basis of history
of anaphylactic reactions or positive food challenge).
Additional enquiries concerning the twelve months pre-
ceding the study included: asthma symptoms and their
triggering factors; asthma medications; adherence to
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therapy; use of healthcare services. Information about
physical activity and active smoking was obtained dir-
ectly from the child if aged 12 years or over. Lifetime
sensitization assessed by skin-prick testing (defined posi-
tive if at least 1 allergen had a wheal diameter ≥3 mm
larger than the negative control) and/or serum specific
IgEs were obtained from the patients’ clinical charts. All
children were assessed for self-perception of health-
related quality of life (HR-QoL) using the Italian version
of the Paediatric Asthma Quality of Life Questionnaire
[12, 13]. Children aged 12 years or over were also
assessed for self-perception of wellbeing using the
Italian version of the WHO-5 Wellbeing Index [14],
available on https://www.psykiatri-regionh.dk/who-5/
who-5-questionnaires/Pages/default.aspx. A score below
13 indicated poor wellbeing.
At the study entry, body mass index (BMI) was calcu-
lated as weight (kg)/height (m) squared. Obesity was de-
fined as BMI >95th percentile [15]. Each investigator
scored the patient’s ability to use the inhaler properly on
a scale ranging from 0 (totally incorrect execution) to 10
(perfect execution). Blood eosinophil count and total
serum IgE levels were determined. The fraction of ex-
haled nitric oxide (FENO) was measured before spirom-
etry at an exhalation flow rate of 50 mL/s, according to
international guidelines [16]. Short-acting and/or long-
acting bronchodilators and/or leukotriene antagonists
were respectively withheld 8, 24, and 72 h before spir-
ometry. Spirometry was performed in accordance with
international recommendations [17], and z scores
were calculated for FVC, FEV1, FEV1/FVC ratio, and
FEF25–75 [18]. A FEV1 z score ≥ −1.64 was considered
normal.
Data retrieval and monitoring
For data collection, a centralized Web-based system was
developed by the CINECA Inter University Consortium
(Bologna, Italy) based on secure AXMR® technology.
Registered centers accessed the database directly online
using a personal identification and password. The system
automatically performed eligibility checks and then con-
firmed or refused the patient’s enrolment. Data were en-
tered by centers on online electronic forms and stored at
the quality and security procedure-certified CINECA
Data Center. The web-reporting system was always
available to analyze data, with information updated daily.
Data managers (S.M. and F.R.) were properly trained to
use the web-data management system.
Statistical analysis
Results are expressed as medians and ranges for continu-
ous variables, and as percentages for categorical data.
Comparisons were made using Fisher’s exact test and the
Mann–Whitney U test. Characteristics demonstrating
significant differences between SA and NSPA in the uni-
variate analysis were further analyzed by binary logistic re-
gression, adjusting for age, gender, center, and mutual
relationships. We did not include in the multivariable ana-
lysis variables which were highly correlated such as age at
anti-asthma maintenance treatment start, hospital admis-
sions for asthma during the past year, oral steroids for
asthma exacerbations, and parents with workdays lost; we
included instead parental smoking, which was of border-
line significance at the univariate analysis. A two-
sided p < 0.05 was considered significant. Data were
analyzed with SPSS-PC 13.0 (SPSS Inc., Chicago, IL).
Results
Forty-one children with SA and 78 with NSPA were en-
rolled from 16 centers. Subjects with SA had a higher
prevalence of lifetime sensitization to food allergens than
their NSPA peers (p = 0.04), while no significant differ-
ence for sensitization to aeroallergens was observed be-
tween the two groups (Table 1). Children with SA
started anti-asthma maintenance treatment significantly
earlier than NSPA peers (p = 0.04). Moreover, during the
preceding 12 months, SA subjects had more frequent epi-
sodes of hospitalization and emergency-department visits
for asthma, oral steroids for asthma exacerbations, symp-
toms triggered by physical activity (all p values < 0.001),
and nocturnal symptoms (p = 0.049). None of the patients
from either group had been admitted to intensive care
units during the previous year. Comorbidities (i.e. rhino-
conjunctivitis, obesity, and symptoms of chronic sinusitis
and of gastroesophageal reflux) were equally distributed
between the two groups, and the degree of physical activ-
ity was similar. No difference in physical activity was
found between boys and girls in both groups. Only one
patient was an active smoker.
At recruitment, additional controllers to inhaled corti-
costeroids used by the study subjects were long-acting
inhaled bronchodilators (95 % of children with SA versus
47 % of patients with NSPA, p < 0.001), oral Montelukast
(68 % versus 36 %, p < 0.001), maintenance oral steroids
(2 % versus 0 %, p = 0.3), oral sustained release methyl-
xanthines (7 % versus 0 %, p = 0.04), or subcutaneous
Omalizumab (32 % versus 0 %, p < 0.001). Twelve per-
cent of patients with SA and 6 % of children with NSPA
had missed at least one dose of controller medications
more than once a week during the previous six months
(p = 0.3). The inhaler technique was good for both
groups, with a median score of 9 (range, 6–10) for SA
and 9 (range, 5–10) for NSPA subjects (p = 0.6).
Parents of children with SA had lost more working
days in the previous year (12 versus 5, p = 0.01). No sig-
nificant differences were observed between the groups
for other parental and environmental characteristics, al-
though children with SA tended to have a higher
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prevalence of smoking parents (54 % versus 36 %, p = 0.08)
(Table 2).
The multiple logistic regression analysis showed that
lifetime sensitization to food allergens, lifetime hospital
admission for asthma, emergency-department visits dur-
ing the past year, and symptoms triggered by physical
activity were independently associated with SA (Table 3).
HR-QoL was significantly worse in SA than NSPA
cases, while the WHO-5 Wellbeing Index was similar in
both groups, with 12 SA (44 %) and 20 NSPA children
(43 %) having an index value lower than 13 (Table 4).
Compared with girls, boys showed lower HR-QoL scores
(physical activity limitation domain: 5.2 versus 6.5, p = 0.03;
symptom domain: 5.5 versus 6.3, p = 0.02; and total score:
5.8 versus 6.5, p = 0.02), but a similar WHO-5 Wellbeing
Index (58 % versus 44 %, p = 0.4).
No differences in eosinophils, total IgE and FENO levels
were observed between the groups (Table 5). Children
with SA had lower FEV1, FEV1/FVC and FEF25–75 z scores
than their NSPA peers (p < 0.001 for each parameter). A
Table 1 Personal characteristics of children with severe asthma (SA) and non-severe persistent asthma (NSPA)
SA NSPA p
(n = 41) (n = 78)
Personal characteristics
Age at the study, yrs 12 (6–17) 12 (6–17) 0.8
Male gender 27 (66) 47 (60) 0.7
Lifetime atopic sensitization to
house dust mites 31 (76) 59 (76) 1
pets dander 21 (51) 47 (60) 0.4
moulds 13 (32) 24 (31) 1
pollen 28 (68) 61 (78) 0.3
cow milk proteins/egg/peanuts 15 (37) 14 (18) 0.04
History of anaphylactic reactions 6 (15) 10 (13) 0.8
Current atopic eczema 10 (24) 11 (14) 0.2
Current food allergies 6 (15) 9 (11) 0.8
Age at onset of asthmatic symptoms, yrs 3 (0–11) 2 (0–12) 0.8
Age at physician’s diagnosis of asthma, yrs 5 (0–11) 6 (0–13) 0.06
Age at anti-asthma maintenance treatment start, yrs 6 (1–12) 7 (1–13) 0.04
Lifetime hospital admissions for asthma 33 (80) 30 (38) <0.001
Hospital admissions for asthma during the past year 12 (29) 3 (4) <0.001
Emergency-department visits for asthma during the past year 19 (46) 8 (10) <0.001
Oral steroids for asthma exacerbation in the past year 32 (78) 34 (44) <0.001
Nocturnal symptoms between exacerbations 22 (54) 26 (33) 0.049
Asthmatic symptoms triggered by
physical activity 36 (88) 41 (53) <0.001
allergens 24 (59) 44 (56) 0.8
airway infections 28 (68) 41 (53) 0.1
fog, humid or cold air, or perceivable odors 19 (46) 29 (37) 0.4
tobacco smoke 9 (22) 10 (13) 0.2
Comorbidities
Current rhinoconjunctivitis 23 (56) 48 (61) 0.7
Obesity 4 (10) 7 (9) 1
Symptoms of chronic sinusitis 4 (10) 2 (3) 0.2
Symptoms of gastro-esophageal reflux 6 (15) 7 (9) 0.4
Regularly playing a sport 26 (63) 51 (65) 0.8
Physically active >5 h/wk 10 (24) 21 (27) 0.8
Data are presented as number of patients (%) or median values (range)
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normal FEV1 was found in 23 (56 %) SA and 69 (88 %)
NSPA patients (p < 0.001).
Discussion
The careful characterization of children with SA is consid-
ered an important step towards improving the knowledge
of this small but very challenging group of patients [2, 5].
This is one of the few studies describing the distinguishing
features of SA in children and adolescents in Europe.
Hospital admissions for asthma, emergency-department
visits during the past year, symptoms triggered by physical
activity, lower spirometric values, and worse HR-QoL, but
not well-being index, were differentiating features of SA
versus NSPA. Current signs and symptoms possibly asso-
ciated with atopy (i.e. rhinoconjunctivitis and eczema), eo-
sinophil count, total IgE levels, and FENO values were
similar in children with SA and NSPA, while lifetime
sensitization to food allergens was an independent factor
associated with SA. Home environment was similar in
both groups, even though children with SA had a border-
line higher prevalence of smoking parents.
SA in children is a challenging disorder with signifi-
cant public health implications [1, 2, 19]. Unsurprisingly,
in this study the occurrence of hospital admissions and
emergency-department visits for asthma was a discrim-
inating feature of SA versus NSPA. Nevertheless, 20 % of
patients with SA had never been hospitalized, 71 % and
54 % were not hospitalized or admitted to the emer-
gency department during the year preceding the study,
and none had been admitted to intensive care units dur-
ing the previous year. These findings are consistent with
an earlier report from Sweden [9], where criteria for pa-
tient inclusion were similar to ours, while children en-
rolled in 5 specialized USA centers participating in the
Severe Asthma Research Program [7] and those re-
cruited in 12 specialized French centers at the beginning
of Omalizumab treatment [20] had more severe exacer-
bations or at least required a larger utilization of health
care services. Furthermore, most of our patients with SA
regularly play a sport and are as physically active as their
peers with NSPA.
Previous studies have highlighted an association be-
tween increasing asthma severity in children and both re-
duced HR-QoL and parents’ work attendance [10, 21, 22].
Asthma symptoms not only affect children physically, but
also impair them and their families socially and emotionally
Table 2 Family and environmental characteristics of children with severe asthma (SA) and non-severe persistent asthma (NSPA)
SA NSPA p
(n = 41) (n = 78)
Family characteristics
At least one parent born in Italy 37 (90) 73 (94) 0.5
Parental education beyond high school 6 (15) 19 (24) 0.2
At least one asthmatic parent 36 (88) 71 (91) 0.7
Parents with workdays lost during the past year 16 (39) 16 (21) 0.049
Environmental characteristics
At least one smoking parent 22 (54) 28 (36) 0.08
Number of cohabitants 3 (1–7) 3 (1–6) 1
Dampness in the home 17 (41) 27 (35) 0.5
Pets at home 10 (24) 23 (29) 0.7
Heavy traffic in the residence street 8 (19) 13 (17) 0.8
Data are presented as number of patients (%) or median values (range)
Table 3 Characteristics associated with severe asthma at logistic regression analysis in 41 patients with SA compared to 78 NSPA
children
OR 95 % CI p
Lifetime atopic sensitization to cow’s milk proteins/egg/peanuts 4.73 1.21–18.53 0.03
Lifetime hospital admission for asthma 3.71 1.11–12.33 0.03
Emergency-department visit for asthma during the past year 11.98 2.70–53.11 0.001
Nocturnal symptoms between exacerbations 1.16 0.34–3.97 0.8
Asthmatic symptoms triggered by physical activity 12.78 2.66–61.40 0.001
At least one smoking parent 1.54 0.45–5.25 0.5
OR odds ratio; CI confidence interval
Adjustments were made for all the listed factors and for age, gender, and center
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[10, 21, 22]. In line with previous observations, this study
demonstrates that poor HR-QoL strongly discriminates SA
from NSPA. Interestingly, in our study girls with SA re-
ported a significantly better HR-QoL than boys. Such gen-
der distinction could reflect different psychological
responses to limitations imposed by asthma (e.g. on phys-
ical activity) rather than actual differences in the disease it-
self. Moreover, our patients with SA had similar Wellbeing
Indexes to peers with NSPA, with no gender differences. Of
note, both groups had a median index very close to the
poor wellbeing threshold (set at 13), the cut-off value below
which it is recommended to test the patient for depression
[14]. This finding has never been reported in children with
SA and is consistent with the observation that the preva-
lence of anxiety and depressive disorders is significant
among asthmatic patients, particularly adolescents [19, 23].
A more in-depth analysis of psychological aspects in chil-
dren and adolescents with SA would be worthy also for
identifying specific interventions that could help reduce
asthma morbidity.
According to some [8, 10] but not all [4] previous
studies, most of our SA patients were sensitized to aero-
allergens, with no prevalence difference from the NSPA
group. Nevertheless, we highlight the novel finding that
lifetime sensitization to food allergens was more fre-
quent in SA than in NSPA. Although children with
asthma show a strikingly high prevalence of food
sensitization [24, 25], the majority have no clinical food
allergies [25], which is consistent with the presence of
current food allergies in only a third of our children sen-
sitized to food. It is well known that children with food
sensitization have increased asthma morbidity, with a
higher hospitalization frequency and greater need for
steroid medications [26], and even if they have developed
tolerance to food allergens by school-age, previous
sensitization still represents a risk factor for later asthma
development [27, 28]. Our results confirm and extend
these findings by demonstrating that lifetime sensitization
to food allergens is an independent risk factor for SA.
Reduction in FEV1 is often used to define childhood
asthma severity in treatment guidelines [1] and clinical
studies [7, 9, 29]. Interestingly, while our SA patients
showed worse spirometric measures than their NSPA
peers, more than half had a normal FEV1, indicating that
a reduction in FEV1 is an insensitive measure of SA. In-
deed, contrary to adults, spirometry may be a poor pre-
dictor of asthma severity in children, and previous
studies examining the relationship between FEV1 and
Table 4 Quality-of-life and wellbeing scores in children with severe asthma (SA) and non-severe persistent asthma (NSPA)
SA NSPA p
(n = 41) (n = 78)
HR-QoL scores
Physical activity limitation domain 5.8 (2.0–7.0) 6.4 (3.4–7.0) 0.01
Symptom domain 5.9 (1.8–7.0) 6.5 (3.5–7.0) 0.01
Emotional function domain 6.4 (2.1–7.0) 6.9 (2.9–7.0) 0.02
Total score 5.9 (2.3–7.0) 6.6 (3.7–7.0) 0.005
WHO-5 Wellbeing Index, %a 13 (7–24) 14 (5–25) 1
HR-QoL, health-related quality of life; WHO, World Health Organization
Data are presented as median values (range)
a Only administered to children aged 12 years or over (27 and 47 subjects in the SA and NSPA groups, respectively)
Table 5 Laboratory results of children with severe asthma (SA) and non-severe persistent asthma (NSPA)
SA NSPA p
(n = 41) (n = 78)
Eosinophil count, 106 · L−1 420 (10–1340) 485 (3–2420) 1
Serum total IgE levels, kUA/L 506 (27–4100) 541 (39–15850) 0.9
FENO, ppb 30 (2–196) 21 (2–156) 0.3
Spirometry data
FVC, z score −0.3 (−4.1–2.1) 0.2 (−3.4–2.9) 0.08
FEV1, z score −1.4 (−4.4–2.3) −0.2 (−3.3–2.4) <0.001
FEV1/FVC, z score −1.7 (−3.7–2.9) −0.1 (−2.9–3.0) <0.001
FEF25–75, z score −2.0 (−5.2–2.5) −0.5 (−3.8–2.0) <0.001
FENO, fraction of exhaled nitric oxide; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 s; FEF25–75, forced expiratory flow between 25 % and 75 % of
vital capacity
Data are presented as median values (range)
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the childhood asthma severity level have demonstrated
very weak correlations between lung function and asth-
matic symptoms [19, 29, 30]. FENO levels were similar
in both groups, in line with some previous studies
showing no significant increase in FENO values in SA
children [9, 21, 29]. As all our subjects were on regular
steroids maintenance therapy, the lack of any difference in
FENO between SA and NSPA may be explained by the
anti-inflammatory effects of the treatment.
Unlike previous studies [8–10], a number of comor-
bidities (i.e. rhinoconjunctivitis, obesity, and symptoms
of sinusitis and of gastroesophageal reflux), family char-
acteristics (namely, parental asthma and education), and
environmental exposures (i.e. dampness at home and ex-
posure to heavy traffic) were similar in SA versus NSPA
patients. Exposure to smoking at home was indeed more
prevalent in patients with SA, although the difference
did not reach statistical significance possibly because of
the low sample size.
We used a national online web-based system to collect
a large number of personal, family and environmental
data from children with SA and NSPA enrolled in vari-
ous Italian centers. The main strengths of this system
are that it allows for collecting huge amounts of longitu-
dinal data, and ideally enables inclusion of foreign pa-
tients for larger international studies. Another strength
of our study is that, unlike previous reports [6–8, 10],
we included only children with refractory asthma or in
whom treatment of comorbidities has been addressed as
per the ERS/ATS Guidelines definition [2].
This study has limitations. Firstly, the study was not
designed to assess the prevalence of SA in Italy, which
would have been difficult to achieve considering the ex-
tension of the country. Secondly, the number of patients
recruited was small and this prevented us from drawing
definite conclusions on the lack of difference in a few
variables between patients with SA and NSPA. However,
our sample size is similar to that of previous European
studies [8–10]. Finally, exposure to smoke and adherence
to prescribed medication were assessed via self-reporting.
Nonetheless, the lack of any adherence differences
between SA and NSPA suggests that this shortcoming did
not have much impact on our findings.
Conclusions
This study shows that, compared to children and adoles-
cents with NSPA, discriminating features of SA include
lifetime sensitization to food allergens, worse airway ob-
struction, and increased use of health-care resources. Apart
from a greater exposure to parental smoking, environmen-
tal, family and personal characteristics as well as comorbidi-
ties of our SA patients are not different from those of their
peers with NSPA. Finally, SA patients have worse HR-QoL
than NSPA peers, and the perception of wellbeing is
borderline in both groups, suggesting that the psycho-
logical aspects in these patients deserve further
investigation.
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